Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Farrell, Do you recall how much money the federal government spent buying Remdesivir and Chloroquine as treatments for Covid-19?
What part “makes no sense”?
I don’t think there will be any “partnership offers” by January 1st that are “attractive” enough. After one or two billion dollars in direct sales of Brilacidin to governments around the world, then the offers that come in may be “attractive” enough. Those offers will certainly be closer to full value.
I would think that scientists at one of the RBLs would already be testing Brilacidin against some of those other viruses (like the flu). I certainly hope that in the very near future we get to see those results.
Dr. Paddleboarder said,
SA is apparently helping the MMs keep a lid on the price. It wouldn’t be the first time they worked with others against this stock.
Dorus... It’s appropriate. I like it!
TheDane said,
Sticky material...
Just one million doses at even $500 per is $500,000,000 dollars. 100 million doses at $500 per is $50 BILLION dollars.
Here Today said,
Exactly!
Williamssc said,
Could we be experiencing a mutually agreed “quiet period” while negotiations with a BP are on-going?
TheDane said,
Glad you’re better. Welcome back!
I wonder if something like that would require FDA approval? ANY cash flow would greatly enhance our prospects.
Dr. Paddleboarder said,
I have long thought that the royalty amount should be progressive. (Ex, 20% of the 1st billion in annual revenue. 35% of the 2nd billion in annual revenue and 50% thereafter.)
Petemantx said,
As I recall there was also mention that too many people were no coming back in for the follow up treatments. Remember, the comparator, Daptomycin, was administered by IV for 7 consecutive days. That means those treated with Brilacidin (and a placebo combination) also had to be administered for 7 days so the patients (and the doctors) would not know who was treated with what. A significant number not completing the treatments would, of course, confound the results.
KarinCA said,
This is beginning to look like a recurring theme. The price spikes early in the day only to be horse collared and pulled down by the market makers.
As I’ve said before, I am not a doctor but I have stayed at a Holiday Inn Express so take my comments for what they may be worth.
Brilacidin kills the virus. Each dead virus means one less infected human cell. The fewer infected human cells the better chance the human host has to survive. That does not mean that the host will necessarily survive. If too much damage has already been done before B has been administered, it may be too late. However, Brilacidin also has other MOAs that could benefit the host as well. Since there is no way to know when it’s too late, why not take B and hope for the best, even when it may be too late.
That said, they probably do not want to put patients with late stage Covid19 in the upcoming trial for fear of confounding the results. But once approved, I see no reason why Brilacidin should be withheld from patients with late stage disease.
JMHO...
Duchamp asked,
Nice find! Thanks thekidzcollegephund...
From the article... Based on the RT-PCR analysis of samples collected from the buccal cavity during screening for the SARS-CoV-2 infection, a number of defensin genes were shown to be downregulated, suggesting that the “innate immunity provided by defensins is or may be compromised.” The study authors go on to suggest “defensin peptides could be attractive therapeutic options.”
921 in NC...
https://covid19.ncdhhs.gov/dashboard/hospitalizations
WarrenThomas said,
LOL! So predictable...
That was a missed opportunity and very disappointing. I thought this new guy was going to be more cognizant of PR and shareholder communications.
Buckysherm said,
Too bad they didn’t have Brilacidin for OM when you needed it. Glad things are going well for you now and look forward to celebrating with you in the near future!
I hope you won and are on the backside of that battle. Did you have trouble with Oral Mucocitis?
Waltierre said,
Good luck and get well soon!
Very interesting indeed!
KMBJN said,
I’m not a Doctor but I have previously stayed at a Holiday Inn Express. My 2 cents? Cancer cells are human cells. Brilacidin has been proven to be safe for human cells, so I think it extremely unlikely that B selectively destroys cancer cells. But then WDIK - After all, it’s been years since I stayed at that Holiday Inn Express...
Basill22 said,
You’re not the only one...
Dall21 said,
You are funny! I can hear Leo laughing now!
Absolutely, sign that deal... IF (and only if) Brilacidin gets the lion’s share of the credit for the effectiveness of the combo drug AND IPIX gets at least 50% of the gross from the sale of the combo drug. So yes, absolutely! Under those circumstances, sign the deal!
Lemonsmith said,
Lemoncat said,
Gee! I wonder why the FDA is not making Brilacidin go back and do some more animal trials? Could it be that Brilacidin has already proven that it’s “delivery mechanism works”...in actual humans? You know I do seem to recall that in the Phase 2 trial for ABSSSI, one thing that Brilacidin proved was that “its delivery mechanism works in a system that somewhat resembles a human system...vessels, membranes, pumps, etc.” Oh wait! Those patients in the ABSSSI trial didn’t just resemble a human system, they WERE human systems, hundreds of them in fact! And Brilacidin worked GREAT!
Lemoncat said,
You are still wrong and “Prurisol IS a shiny example of that.” The mice in the Prurisol trial were even genetically engineered to better reflect human tissue. But while Prurisol worked well for the mice, it did not work in humans.
In the case at hand, we already know from previous trials that Brilacidin’s “delivery mechanism works” in the actual human system. We also know that it kills the virus in human cells at rates approaching 100%. Do you really think that a few tests on animals means that Ab8 is somehow ahead of Brilacidin in the race to prove efficacy in humans? Sorry, but you are just sooo wrong...
Oh, and I know safety is not something you like to focus on, but remember; Brilacidin has been proven to be safe in humans with an SI Rating for Covid of >300. Ab8 has not been proven safe in humans and does it even have an SI Rating for anything? Oh well, one of those articles did mention that they had more animal testing to do before they could talk to the FDA about human testing.
I hear ya!
What am I looking for in Harris’s Twitter feed?
And you are a WRONG yet again. Who said I was “disregarding efficacy”? I specifically stated that it takes both safety and efficacy. And most people familiar with drug testing know that animal testing is NOT a “more advanced efficacy test” than using human cell lines. It is VERY often the case that what works in animals does NOT work in humans. Is this a case of it being “difficult to get a man to understand something, when his salary depends upon his not understanding it”?
Lemoncat said,
@JFM. Understood... and thanks.
Class action? I like it! Give the bastards a taste of their own medicine. And even better, class action lawsuits are generally handled on a contingent fee basis.
Here Today said,
Thanks Loanranger. If they accomplish all these steps for Ab8 by early 2021, that will be very, VERY impressive indeed. Still, if they enroll a Phase 1 trial in early 2021, they still have to successfully complete it before they can begin planning a Phase 2. I think that pretty well makes my point that Brilacidin is more advanced than a drug that still has; to be manufactured, do additional safety assessments in animals, get FDA approval to proceed with trials, and then “register and enroll clinical trials.”
From the article,
Correction, “Why are you interested in only 33% of the company.”
Attilathehunt said,
And you are WRONG yet again. You can set up ”efficacy” as a strawman all you want but that changes nothing. I value both safety and efficacy because it takes both. I say that Brilacidin is more “advanced” because it is. The most “advanced” drug will be the first to market and THAT is why Brilacidin is more “advanced” than Ab8. The most time consuming steps any drug must go through involve human trials. Ab8 has to go through Phase 1 safety trial(s) before it can begin to think about Phase 2 human trials. And since none of the articles I’ve seen on Ab8 even talk about human trials, I think it fair to assume that they are nowhere near ready to start them. Brilacidin’s Phase 2 for Covid will be completed before Ab8 even begins a Phase 1. Meanwhile, Brilacidin is preparing to engage with the FDA even as we speak to start a Phase 2 human trial for Covid. Please read the statement at the bottom of my post.
Lemoncat said,
Yes, absolutely.
Zandant said,
And you are STILL wrong. Brilacidin is far beyond “hamsters and mice” and is well ahead of Ab8 which has not even been proven SAFE in humans.
Lemoncat said,